Add To Watchlist
Share URL
About The Company
CEO
Dr. Peter Salzmann M.B.A., M.D.
Market Cap
2.45 Billion USD
Sector
Healthcare
Website
https://immunovant.comDescription
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
Read More
Overview
Value
2
Growth
2
Health
52
Management
59
Analyst Opinion
60
Total
34
All Scores Out Of 100
Best Features
- Has a low level of debt
- Low preportion of income is paid as dividend 0
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Disliked by Twitter users
- Poor earnings and cashflow growth
Latest News

5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
24/7 Wall Street | 03:53 Fri 20 Jan 2023
Read More →

These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022
24/7 Wall Street | 03:50 Tue 10 Jan 2023
Read More →

Immunovant: argenx At A 10% Valuation, Initiating With A Buy Rating
Seeking Alpha | 13:47 Sun 8 Jan 2023
Read More →

4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
Zacks Investment Research | 14:47 Fri 16 Dec 2022
Read More →
Market Peers
IMVT
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-83.49%
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Neutral
Share Buybacks
-106.26%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
2
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 3.2 USD ✘
Current Price: 19 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-6.75%
PE/Earnings Growth
N/A
Price/Book
5.92x
Growth
Growth Score
2
- ✔ Revenue growth has improved this yeara
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of 0.36% is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of -20.38% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
N/A
Earnings Growth
0.36%
Cashflow Growth
-20.38%
Health
Health Score
52
Altman Z Score
N/A
Piostroski Score
N/A
Debt/Equity
0.01x
Current Assets/Liabilities
11.52x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.00x
Management
Management Score
59
Average Buybacks/Dilution
-106.26%
Recent Buybacks/Dilution
17.78%
5 Year Price Volitility
77.00%
Return On Assets
-35.83%
Return On Capital Employed
-27.95%
Return On Equity
-39.32%
Return On Free Cashflow
221.14%
Return On Investments
N/A
Analysts
Analyst Opinion
60
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Immunovant, Inc.
Currency
USD
Beta
1.087135
Vol Avg
1195632
Ceo
Dr. Peter Salzmann M.B.A., M.D.
Cik
0001764013
Cusip
45258J102
Exchange
NASDAQ Global Select
Full Time Employees
124
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2019-05-10
Address
320 West 37Th Street
City
New York City
State
NEW YORK
Country
US
Zip
10018
Phone
19175803099
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
26
Twitter Sentiment
N/A
Stocktwits Sentiment
51.00